乳腺癌激素治疗 (HT) 会增加静脉血栓栓塞 (VTE) 的风险。本研究探讨了急性 VTE 事件后继续与停止 HT 对 VTE 复发、大出血和死亡率的影响。使用 2001 年 3 月至 2021 年 9 月 RIETE 登记处的数据，我们计算了发病率和比率 (RR) ）对于接受和未接受 HT 的患者的 VTE 事件。 Cox 回归模型评估了继续 HT 的影响。在 479 名发生 VTE（肺栓塞 279 例，孤立性深静脉血栓 200 例）的 HT 乳腺癌女性中，350 例 (73%) 继续 HT。这些女性比停止 HT 的女性稍年长（70 ± 13 岁 vs. 67 ± 16 岁），其他基线特征没有显着差异。在中位随访 294 天中，25 人 (5.2%) 出现 VTE 复发，18 人 (3.7%) 出现大出血，73 人 (15.2%) 死亡。 VTE 复发率在各组之间没有显着差异（RR：1.28，95% CI 0.44-3.75），但在 VTE 后的前三个月除外，在持续 HT 的患者中观察到较高的复发率（每年 6.02/100 名患者）与没有事件）。多变量分析表明，在调整其他血栓栓塞风险因素后，继续 HT 与 VTE 复发无关（调整后的风险比 [aHR] 1.49，95% CI 0.5-4.45）。乳腺癌女性发生 VTE 事件后继续 HT 通常不会影响 VTE 复发。影响 VTE 复发的长期风险，但与前三个月的较高风险相关。这些发现凸显了在此期间进行仔细监控的必要性。版权所有 © 2024 Elsevier Ltd。保留所有权利。

Hormone therapy (HT) for breast cancer is associated with an increased risk of venous thromboembolism (VTE). This study examines the effects of continuing versus discontinuing HT on VTE recurrence, major bleeding, and mortality, after an acute VTE event.Using data in the RIETE-registry from March 2001 through September 2021, we calculated incidence rates and rate-ratios (RR) for VTE events in patients on- and off HT. Cox regression models assessed the impact of HT continuation.Among 479 women with breast cancer on HT who developed VTE (pulmonary embolism 279, isolated deep vein thrombosis 200), 350 (73 %) continued HT. These women were slightly older (70 ± 13 vs. 67 ± 16 years) than those discontinuing HT, with no significant differences in other baseline characteristics. Over a median follow-up of 294 days, 25 (5.2 %) developed VTE recurrences, 18 (3.7 %) had major bleeding, and 73 (15.2 %) died. Rates of VTE recurrence did not differ significantly between groups (RR: 1.28, 95 % CI 0.44-3.75), except in the first three months post-VTE, where a higher rate was observed in those continuing HT (6.02/100 patients-year vs. no events). On multivariable analysis, HT continuation showed no association with VTE recurrences after adjusting for other thromboembolic risk factors (adjusted hazard ratio [aHR] 1.49, 95 % CI 0.5-4.45).Continuing HT after a VTE event in women with breast cancer does not generally affect the long-term risk of VTE recurrences but is associated with a higher risk in the first three months. These findings highlight the need for careful monitoring during this period.Copyright © 2024 Elsevier Ltd. All rights reserved.